Cellular inflammatory and anti-viral effects of BOLD-100, a novel therapeutic agent in development for COVID-19

Bold-100 is a promising new drug that has been studied as a treatment for cancer. Because of the way it works in cells, there is reason to believe that it may also help protect against infections with viruses like SARS-CoV2 (the cause of COVID-19). The purpose of this project is to study the effects of Bold-100 on cells derived from the human intestine, which are susceptible to SARS-CoV2 infection, to help determine the way the drug effects normal cellular functions and their response to viral infections. The results will help to define the potential of Bold-100 as an antiviral drug, as well as its potential uses for other diseases, including intestinal cancers and inflammatory bowel disease.

Faculty Supervisor:

Ted Steiner


William Rees


Bold Therapeutics




Professional, scientific and technical services


University of British Columbia



Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects